Nestlé acquires Aimmune Therapeutics
The Swiss multinational bets on the Pharmaceutical sector, acquiring Palforzia, used to treat peanut allergy, which affects about 240 million people worldwide.
Important acquisition at Nestlé. The Swiss giant is focusing on biotechnology applied to the food sector by buying Aimmune Therapeutics. The company, listed on Nasdaq, has developed a drug, Palforzia, able to contain a specific intolerance: peanut allergy.
Palforzia was approved by the American Food and Drug Administration (FDA) in January 2020 as oral immunotherapy for the mitigation of allergic reactions. It is currently under review with the European and Swiss markets and the final decisions will arrive by the end of 2020 and 2021 respectively.
The deal took place through an opa of $ 34.50 per share, with a premium of 170% compared to Friday’s closing of the Californian group. Nestlé had already bet on the US company, investing 473 million and controlling the 25%.
The American group will continue to operate independently from its Californian headquarters in Brisbane, but will be placed within the Nestlé Health Science (NHSc) department. It will oversee the unit’s pharmaceutical activities worldwide.
“Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives” – said Greg Behar, CEO of NHSc – “Aimmune’s Palforzia, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally.”